Notably, agonists cause desensitization of GnRH‐stimulated gonadotropin secretion and the consequent reduction in circulating sex steroids is exploited to treat hormone‐dependent cancers of the breast, ovary and prostate [981]. Here, GNRH1 is linked to cancer.